International Journal of Tuberculosis and Lung Disease最新文献_第10页

Cost-effectiveness of expanded latent TB infection testing and treatment: Lynn City, Massachusetts, USA. 扩大潜伏肺结核感染检测和治疗的成本效益：美国马萨诸塞州林恩市。

IF 4 3区医学

International Journal of Tuberculosis and Lung Disease Pub Date : 2024-01-01 DOI: 10.5588/ijtld.22.0654

G R Beeler Asay, R Woodruff, D M Sanderson, C F Fisher, S M Marks, V D Green, A M Tibbs, A N Hill, H H Haptu, D McManus, R K Paradise, C Auguste-Nelson, J J Cochran

{"title":"Cost-effectiveness of expanded latent TB infection testing and treatment: Lynn City, Massachusetts, USA.","authors":"G R Beeler Asay, R Woodruff, D M Sanderson, C F Fisher, S M Marks, V D Green, A M Tibbs, A N Hill, H H Haptu, D McManus, R K Paradise, C Auguste-Nelson, J J Cochran","doi":"10.5588/ijtld.22.0654","DOIUrl":"10.5588/ijtld.22.0654","url":null,"abstract":"BACKGROUND: Between October 2016 and March 2019, Lynn Community Health Center in Massachusetts implemented a targeted latent TB infection testing and treatment (TTT) program, increasing testing from a baseline of 1,200 patients tested to an average of 3,531 patients tested, or 9% of the population per year.METHODS: We compared pre-implementation TTT, represented by the first two quarters of implementation data, to TTT, represented by 12 quarters of data. Time, diagnostic, and laboratory resources were estimated using micro-costing. Other cost and testing data were obtained from the electronic health record, pharmaceutical claims, and published reimbursement rates. A Markov cohort model estimated future health outcomes and cost-effectiveness from a societal perspective in 2020 US dollars. Monte Carlo simulation generated 95% uncertainty intervals.RESULTS: The TTT program exhibited extended dominance over baseline pre-intervention testing and had an incremental cost-effectiveness ratio (ICER) of US$52,603 (US$22,008â-\"US$95,360). When compared to baseline pre-TTT testing, the TTT program averted an estimated additional 7.12 TB cases, 3.49 hospitalizations, and 0.16 deaths per lifetime cohort each year.CONCLUSIONS: TTT was more cost-effective than baseline pre-implementation testing. Lynn Community Health Centerâ-™s experience can help inform other clinics considering expanding latent TB infection testing.","PeriodicalId":14411,"journal":{"name":"International Journal of Tuberculosis and Lung Disease","volume":null,"pages":null},"PeriodicalIF":4.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11149049/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139097830","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The urgent need to improve on low implementation rates for TB preventive treatment for people living with HIV. 迫切需要改善艾滋病毒感染者结核病预防治疗执行率低的问题。

IF 4 3区医学

International Journal of Tuberculosis and Lung Disease Pub Date : 2024-01-01 DOI: 10.5588/ijtld.23.0570

M Cossa, D Nguenha, A Houana, J Ehrlich, S Acácio, A L Garcia-Basteiro

引用次数: 0

Estimating TB survival - mind the immortal-time gap. 估算结核病存活率--注意不朽时间的差距。

IF 4 3区医学

International Journal of Tuberculosis and Lung Disease Pub Date : 2024-01-01 DOI: 10.5588/ijtld.23.0453

R M G J Houben, T McCaffrey, E W Tiemersma, P Y Khan

引用次数: 0

Monitoring TB infection in contact cases: the impact of the COVID-19 pandemic. 监测接触病例中的肺结核感染：COVID-19 大流行的影响。

IF 4 3区医学

International Journal of Tuberculosis and Lung Disease Pub Date : 2024-01-01 DOI: 10.5588/ijtld.23.0100

M Tyufekchieva, T Varleva

引用次数: 0

Anti-tuberculosis activity of morusin: a promising flavonoid from white mulberry. morusin的抗结核活性：白桑中一种有前途的黄酮类化合物。

IF 4 3区医学

International Journal of Tuberculosis and Lung Disease Pub Date : 2024-01-01 DOI: 10.5588/ijtld.23.0224

K Yildirim, S Bozkurt, H H Basibuyuk, A Y Coban

{"title":"Anti-tuberculosis activity of morusin: a promising flavonoid from white mulberry.","authors":"K Yildirim, S Bozkurt, H H Basibuyuk, A Y Coban","doi":"10.5588/ijtld.23.0224","DOIUrl":"10.5588/ijtld.23.0224","url":null,"abstract":"BACKGROUND: TB has remained a significant public health concern from historical times to the present day. Each year, growing drug resistance problems necessitate the discovery of new drugs and drug precursors for TB treatment. Morusin is an important flavone found in the bark of white mulberry (Morus alba L.) with anti-oxidant, antimicrobial, anti-tumour, anti-inflammatory and antiallergic activity.OBJECTIVE: To determine the anti-TB efficacy of morusin on Mycobacterium tuberculosis strains.DESIGN: Anti-TB efficacy of morusin was tested on H37Ra (American Type Culture Collection [ATCC] 25177), H37Rv (ATCC 27294), ATCC 35822 (isoniazid [INH] resistant), ATCC 35838 (rifampicin [RIF] resistant), and ATCC 35820 (streptomycin [SM] resistant) standard strains and its efficacy was determined using nitrate reductase assay (NRA).RESULTS: The minimum inhibitory concentration (MIC) of morusin was tested in the range of 53.83â-\"0.21 Î¼g/ml. The MIC for H37Ra (ATCC 25177), H37Rv (ATCC 27294) and ATCC 35838 (RIF-resistant) strains were found to be 6.72 Î¼g/ml, and this was 13.45 Î¼g/ml for the ATCC 35822 (INHresistant) and ATCC 35820 (SM-resistant) strains.CONCLUSION: To consider morusin as a viable alternative or precursor drug for TB treatment, it is imperative to conduct an exhaustive examination of its mechanism of action and conduct in vitro studies using clinical isolates.","PeriodicalId":14411,"journal":{"name":"International Journal of Tuberculosis and Lung Disease","volume":null,"pages":null},"PeriodicalIF":4.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139097828","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Ethambutol-induced optic neuropathy: should we mandate ophthalmic examination in TB treatment? 乙胺丁醇诱发的视神经病变：我们是否应该在结核病治疗中强制要求进行眼科检查？

IF 4 3区医学

International Journal of Tuberculosis and Lung Disease Pub Date : 2024-01-01 DOI: 10.5588/ijtld.23.0304

S R Kumar, S S Hissar, P M Ramesh, M Shanmugam, V Kalaiselvan, J Prakash, C Padmapriyadarsini

引用次数: 0

Literature Highlights. 文学亮点。

IF 4 3区医学

International Journal of Tuberculosis and Lung Disease Pub Date : 2023-12-01 DOI: 10.5588/ijtld.23.9912

M Jankovic Makek, J M Trauer, H D Blackbourn

引用次数: 0

Assessing patient satisfaction with video-supported therapy for drug-susceptible TB treatment. 评估患者对药物敏感结核治疗视频支持疗法的满意度。

IF 4 3区医学

International Journal of Tuberculosis and Lung Disease Pub Date : 2023-12-01 DOI: 10.5588/ijtld.23.0227

S M Ragheb, J B White, J Jarand, D A Fisher, R K Lim

引用次数: 0

Atorvastatin improves sputum conversion and chest X-ray severity score. 阿托伐他汀改善痰转化和胸部x线严重程度评分。

IF 4 3区医学

International Journal of Tuberculosis and Lung Disease Pub Date : 2023-12-01 DOI: 10.5588/ijtld.23.0190

O O Adewole, B A Omotoso, M Ogunsina, A Aminu, O Ayoola, T Adedeji, O F Awopeju, O M Sogaolu, T O Adewole, A O Odeyemi, E Jiya, V Andero, O Ojo, K Toyin, A O Akintomide, G E Erhabor

{"title":"Atorvastatin improves sputum conversion and chest X-ray severity score.","authors":"O O Adewole, B A Omotoso, M Ogunsina, A Aminu, O Ayoola, T Adedeji, O F Awopeju, O M Sogaolu, T O Adewole, A O Odeyemi, E Jiya, V Andero, O Ojo, K Toyin, A O Akintomide, G E Erhabor","doi":"10.5588/ijtld.23.0190","DOIUrl":"10.5588/ijtld.23.0190","url":null,"abstract":"BACKGROUND: We report the results of a phase IIB study investigating the safety and effectiveness of atorvastatin use with standard anti-TB drugs.METHODS: In this multicentre, open-labelled study, we recruited treatment-naÏve patients with uncomplicated pulmonary TB aged at least 18 years. Participants were randomly assigned to standard-of-care or standard-of-care plus oral dose of atorvastatin (40 mg) daily for 2 months. Primary end points were safety measured by the number of participants with severe adverse events and effectiveness measured by the number of participants with negative sputum culture. Secondary endpoint was chest X-ray (CXR) severity score.RESULTS: Of the 185 participants screened, 150 were enrolled and equally assigned to the standard-of-care and atorvastatin groups. Adverse event severity was similar in the two groups. There was increased frequency of muscle pain in the trial group (12/75, 16% vs. 4/75, 5%). For efficacy analysis, respectively 64 (97%) and 57 (85.1%) patients in the trial and control groups had culture-negative results (P = 0.02) and experienced a reduction in CXR severity score of respectively 37% and 22%, with a mean difference of 1.4-4.9%.CONCLUSION: Atorvastatin is safe and associated with improved microbiological and radiological outcomes in TB.","PeriodicalId":14411,"journal":{"name":"International Journal of Tuberculosis and Lung Disease","volume":null,"pages":null},"PeriodicalIF":4.0,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138477693","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Challenges and opportunities for TB elimination in Suriname. 苏里南消除结核病的挑战和机遇。

IF 4 3区医学

International Journal of Tuberculosis and Lung Disease Pub Date : 2023-12-01 DOI: 10.5588/ijtld.23.0309

E Commiesie, D Stijnberg, J van den Boogaard, F Gopie, S Vreden, G de Vries

引用次数: 0